R&D

Target Screening Platform Our pipeline strategy for both Category I innovative drugs and Category II modified new drugs begins with identifying unmet clinical needs, then systematically evaluates potential targets based on their biological mechanisms, translational research data, and real-world evidence to select promising candidates with differentiated advantages. For each target under consideration, we conduct comprehensive evaluation — analyzing its mechanism of action, disease relevance, and therapeutic potential to predict both efficacy and safety profiles.

Innovative Drug Discovery Platform We have established a proprietary oral small-molecule drug design platform that designed to accelerate the identification and optimization of high-quality drug candidates while enhancing R&D efficiency and success rates. This platform focuses on therapeutically important target classes — including G protein-coupled receptors, kinases, and proteases — which regulate critical physiological and pathological processes, enabling the rational design of novel compounds with optimal oral bioavailability and target specificity.

Clinical Development Technology Platform Our clinical development platform oversees the end-to-end design and execution of clinical trials for innovative drugs, incorporating preclinical findings, target mechanisms, and fundamental medical research to optimize trial protocols. During trialimplementation, we address compound-specific technical challenges through close collaboration with leading hospitals and healthcare professionals.

CMC Development Platform We have established several key platform technologies: (i) API development technologies encompassing chiral drug synthesis, crystallization engineering, and salt formation; (ii) novel formulation including solubility enhancement for poorly soluble drugs,sustained-release formulations, and fixed-dose combination; and (iii)quality-focused analytical tools including analytical method development, impurity profile characterization, and genotoxic impurity detection. Our CMC development platform was instrumental to the successful commercialization of marketed products, including our Category II modified new drug, Zuoyu, and multiple first-to-market generic products in China.